The hallmarks of cancer

Concept

The hallmarks of cancer

T-098Home BU-307Threads regulation · information

Statement

The capabilities a tumour must acquire.

Why it matters

oncogenes-tumour-suppressors and cell-cycle-checkpoints describe specific molecular lesions and surveillance mechanisms that can go wrong in an individual cell; the hallmarks framework organises the very large number of possible specific mutations into a small, recurring set of functional capabilities that essentially every cancer must acquire, regardless of which specific genes happen to be altered in a given patient's tumour. It is what allows cancer biology to be taught (and researched) at the level of general principles, rather than as an unmanageably long list of disease-specific gene lists.

The framework also directly motivates clonal-evolution-of-tumours: because acquiring every hallmark within one cell lineage generally requires several sequential genetic changes, cancer development is naturally understood as a multistep, Darwinian process of mutation and selection occurring within the body over a patient's lifetime, rather than the result of any single mutational event.

Hypotheses

Cancer arises from an accumulation of somatic changes in a single cell lineage, not from a single mutation alone.This is the basis of "multistep tumorigenesis": a cell carrying only one cancer-associated mutation is not, on its own, generally sufficient to produce a clinically significant tumour, since the surveillance mechanisms described in cell-cycle-checkpoints and programmed cell death would typically still catch and eliminate it. The specific genes altered differ enormously between individual cancers, but the functional capability gained recurs across cancers.Hallmarks are defined at the level of acquired capability (e.g. evading growth suppression), not at the level of a specific gene identity, precisely because the underlying genetic lesions producing that same capability vary enormously between cancer types, and even between different patients with what is nominally the "same" cancer type.

Proof

\text{Sustained proliferative signalling: cancer cells drive their own growth-signal pathways independent of the external growth-factor cues that restrain proliferation in healthy tissue.}

A constitutively active oncogene (oncogenes-tumour-suppressors), for example, can keep a growth-promoting signalling pathway switched on regardless of whether the normal external growth signal is actually present, removing one of the principal restraints on cell division that healthy tissue relies on. A

\text{Evading growth suppressors and resisting cell death: tumour-suppressor pathways and cell-cycle checkpoints must be inactivated or bypassed, alongside evasion of apoptosis.}

The surveillance machinery cell-cycle-checkpoints describes, which normally halts or eliminates a cell accumulating damage, must be disabled or evaded for a damaged, proliferating cell lineage to persist and continue accumulating further changes rather than being arrested or eliminated. A

\text{Enabling replicative immortality: cancer cells commonly reactivate telomerase (or an alternative telomere-maintenance mechanism) to escape the finite division limit normal somatic cells face.}

Normal somatic cells have a finite number of possible divisions, set by progressive telomere shortening at each division; reactivating telomerase (normally active mainly in germline and some stem cells, not most differentiated somatic tissue) removes this limit, allowing indefinite division rather than the senescence or crisis a normal cell lineage would eventually reach. A

\text{Inducing angiogenesis and activating invasion/metastasis: a growing tumour requires its own blood supply and the ability to invade surrounding tissue and disseminate.}

A tumour growing beyond a small size requires new blood vessel formation (angiogenesis-metastasis) to obtain sufficient oxygen and nutrients; acquiring the further ability to invade surrounding tissue and disseminate to distant sites is what converts a localised growth into a systemic, generally far more dangerous disease. B

\text{Because acquiring all these capabilities in one lineage requires several sequential, individually rare changes, tumour development is well modelled as clonal evolution: successive mutation and selection for the fastest-growing/most-invasive clone.}

This is the direct link to clonal-evolution-of-tumours: because each individual genetic or epigenetic change required is comparatively rare in any single cell, and a cell lineage must accumulate several of them together, cancer progression proceeds through iterated rounds of mutation and selection within the body, directly analogous to Darwinian evolution acting over a patient's lifetime rather than across generations. B

Result

\text{Cancer} = \text{acquisition, over successive somatic generations, of a small recurring set of functional capabilities}

Reading. Regardless of which specific genes happen to be mutated in a given tumour, a cancer must acquire the same recurring handful of capabilities — proliferative independence, growth-suppressor/death evasion, replicative immortality, angiogenesis, and invasion/metastasis — to progress from an aberrant cell to a clinically significant, potentially lethal disease.

Scope. A general organising framework across essentially all cancer types; the specific genes and mutational routes to each hallmark vary enormously by cancer type and patient, and later refinements of the framework add further capabilities (reprogrammed metabolism, immune evasion) beyond the original core set developed here.

Corollaries & converses

oncogenes-tumour-suppressors supplies the specific molecular-genetic mechanism most directly underlying hallmarks 1 and 2 (proliferative signalling and growth-suppressor evasion).
cell-cycle-checkpoints is precisely the surveillance system hallmark 2 must defeat for a damaged cell lineage to persist and progress rather than being arrested or eliminated.
clonal-evolution-of-tumours is the process by which a tumour acquires the hallmarks sequentially, cell generation by cell generation, over the course of tumour progression.

Fails without

A cell acquires only some hallmark capabilities (Hypotheses): for example, proliferative independence alone, without also evading apoptosis or growth suppression — the surviving surveillance mechanisms (cell-cycle-checkpoints, programmed cell death) would generally still eliminate or arrest such a partially altered cell, which is precisely why a single oncogenic mutation alone is not usually sufficient to cause clinically significant cancer.
The tumour fails to induce angiogenesis (Step 4): without new blood vessel formation, a solid tumour's growth is limited to roughly the distance oxygen and nutrients can diffuse from existing vasculature, generally on the order of a millimetre or so; a tumour lacking this capability therefore cannot progress beyond a small, often clinically undetected size, regardless of how successfully it has acquired the other hallmark capabilities.

Common errors

Assuming a single mutation is sufficient to cause cancer, rather than the accumulation of multiple hallmark capabilities through a multistep process (Hypotheses).
Assuming all cancers, or all cases of a given cancer type, share the identical mutated genes; the hallmarks framework is specifically defined at the level of functional capability rather than specific gene identity for exactly this reason (Hypotheses).
Conflating a benign tumour or growth (which may show excess proliferation but lacks invasive/metastatic capability, hallmark 5) with cancer proper, which by definition has also acquired the capacity to invade and potentially spread.
Assuming metastasis simply means "spreading" in a loose sense; it specifically requires a further, non-trivial set of acquired capabilities (local invasion, survival in circulation, colonisation of a distant site) beyond mere local growth (Step 4).

Discussion

Douglas Hanahan and Robert Weinberg's original hallmarks framework was published in the journal Cell in 2000, organising decades of accumulated cancer research into the small set of core capabilities developed here; an updated version, published in 2011, extended the framework with two further hallmarks (reprogrammed energy metabolism and evasion of immune destruction) and two "enabling characteristics" underlying the others (genome instability and tumour-promoting inflammation).

Because the specific route to a given hallmark varies so much between cancer types, targeted cancer therapies are increasingly designed around which specific hallmark-enabling mutation or pathway a given patient's tumour actually carries (e.g. targeting a specific activated oncogene directly), rather than using a single uniform treatment across all cancers presenting with superficially similar symptoms or tissue of origin.

Common misconception: that cancer is fundamentally a single disease with one common cause. The hallmarks framework's central point is closer to the opposite: cancer is a very large family of diseases, united not by sharing the same causal mutations but by convergently acquiring the same small set of functional capabilities through many different possible molecular routes.

Worked examples

\text{Tumour carries an activating mutation in a growth-signalling oncogene (e.g. RAS) plus loss of a tumour-suppressor gene (e.g. p53).}

The RAS mutation directly satisfies hallmark 1 (sustained proliferative signalling, keeping the growth pathway active without needing an external cue); the p53 loss directly satisfies part of hallmark 2 (evading growth suppression and apoptosis, since p53 normally triggers cell-cycle arrest or programmed death in response to damage) — together, two independent mutations jointly satisfying two separate hallmark capabilities. A

\text{This same two-mutation combination alone is still generally insufficient for a clinically significant tumour.}

Consistent with Step 5 of the Proof, this cell lineage has acquired only two of the several hallmark capabilities; without also acquiring replicative immortality, angiogenesis, and invasive/metastatic capability, further sequential changes are still required before the lineage can progress to a clinically significant, invasive cancer. B

\text{Two hallmark-enabling mutations} \Rightarrow \text{necessary but not sufficient; further sequential changes still required}

Reading. Even a well-known, clinically important combination of mutations satisfies only some of the hallmark capabilities a fully progressed cancer requires, directly illustrating the multistep, sequential nature of tumorigenesis the Hypotheses describe.

Scope. The same reasoning — identify which specific hallmark(s) a given mutation or combination satisfies, and note which remain unaddressed — applies to any candidate combination of cancer-associated genetic changes.

Problems

A tumour biopsy shows evidence of new blood vessel growth throughout the tumour mass. Which hallmark capability does this most directly indicate has been acquired, and why is this capability necessary for the tumour to grow beyond a small size?
Solution
This indicates hallmark 4, induced angiogenesis (Step 4 of the Proof). It is necessary because a solid tumour's growth without its own blood supply is limited to roughly the distance oxygen and nutrients can diffuse from pre-existing vasculature (Fails without); inducing new vessel growth removes this diffusion-distance limit and allows continued growth beyond that small size.
Explain why a cell with a mutation that activates telomerase, but no other cancer-associated changes, is very unlikely on its own to progress to a clinically significant cancer.
Solution
Telomerase activation alone satisfies only hallmark 3 (replicative immortality); by the Hypotheses' multistep-accumulation requirement, this single change does not also provide sustained proliferative signalling, evasion of growth suppression and apoptosis, angiogenesis, or invasive/metastatic capability. A cell with only this one capability generally still lacks the growth-driving and death-evading changes needed to proliferate excessively in the first place, and remains subject to the surveillance mechanisms (cell-cycle-checkpoints) that would ordinarily still restrain it.
Two patients have tumours classified as the same cancer type by tissue of origin, but genetic sequencing reveals they carry almost entirely different sets of mutated genes. Explain, using the Hypotheses, how both can nonetheless be correctly described as cancer.
Solution
The hallmarks framework defines cancer at the level of acquired functional capability, not specific gene identity (Hypotheses); provided each tumour has independently acquired the same recurring set of capabilities (sustained proliferation, evaded growth suppression, replicative immortality, angiogenesis, invasion/metastasis) via its own specific combination of mutations, both tumours satisfy the definition of cancer, even though the underlying genetic routes taken to reach that same set of capabilities differ substantially between the two patients.